KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Other Non-Current Liabilities (2018 - 2025)

Historic Other Non-Current Liabilities for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $1.5 million.

  • Castle Biosciences' Other Non-Current Liabilities changed N/A to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year change of. This contributed to the annual value of $25000.0 for FY2023, which is 7222.22% down from last year.
  • Latest data reveals that Castle Biosciences reported Other Non-Current Liabilities of $1.5 million as of Q3 2025.
  • Over the past 5 years, Castle Biosciences' Other Non-Current Liabilities peaked at $18.3 million during Q4 2021, and registered a low of $16000.0 during Q1 2024.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $95000.0 (2022), whereas its average is $2.1 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 168235.87% in 2021, then tumbled by 9950.78% in 2022.
  • Castle Biosciences' Other Non-Current Liabilities (Quarter) stood at $18.3 million in 2021, then tumbled by 99.51% to $90000.0 in 2022, then crashed by 72.22% to $25000.0 in 2023, then plummeted by 36.0% to $16000.0 in 2024, then skyrocketed by 9275.0% to $1.5 million in 2025.
  • Its Other Non-Current Liabilities was $1.5 million in Q3 2025, compared to $1.5 million in Q2 2025 and $16000.0 in Q1 2024.